Eric Sheldon

2.3k total citations
37 papers, 1.6k citations indexed

About

Eric Sheldon is a scholar working on Epidemiology, Pharmacology and Infectious Diseases. According to data from OpenAlex, Eric Sheldon has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 12 papers in Pharmacology and 8 papers in Infectious Diseases. Recurrent topics in Eric Sheldon's work include Influenza Virus Research Studies (11 papers), Inflammatory mediators and NSAID effects (11 papers) and Respiratory viral infections research (10 papers). Eric Sheldon is often cited by papers focused on Influenza Virus Research Studies (11 papers), Inflammatory mediators and NSAID effects (11 papers) and Respiratory viral infections research (10 papers). Eric Sheldon collaborates with scholars based in United States, Canada and Belgium. Eric Sheldon's co-authors include Mark M. Blatter, Martine Denis, Eric Plennevaux, Francis X. Burch, C. Codding, Nachiket Patel, George Risi, Louis Fries, Filip Dubovsky and C. Birbara and has published in prestigious journals such as The Lancet, Spine and The Journal of Infectious Diseases.

In The Last Decade

Eric Sheldon

37 papers receiving 1.5k citations

Peers

Countries citing papers authored by Eric Sheldon

Since Specialization

Citations

This map shows the geographic impact of Eric Sheldon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Sheldon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Sheldon more than expected).

Fields of papers citing papers by Eric Sheldon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Sheldon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Sheldon. The network helps show where Eric Sheldon may publish in the future.

Co-authorship network of co-authors of Eric Sheldon

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Sheldon. A scholar is included among the top collaborators of Eric Sheldon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Sheldon. Eric Sheldon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial 2017 ·Vaccine ·(unknown), (unknown), Eric Sheldon, Louise Frenette, Laurence Chu, Damien Friel, Mamadou Dramé, David W. Vaughn, Bruce L. Innis, Anne Schuind	12
2	Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial 2017 ·Vaccine ·(unknown), Murdo Ferguson, Eric Sheldon, Nathan Segall, Laurence Chu, (unknown), (unknown), Damien Friel, Jyoti Soni, Ping Li, Bruce L. Innis, Anne Schuind	10
3	Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study 2016 ·Vaccine ·Robert W. Frenck, C. Buddy Creech, Eric Sheldon, David Seiden, Martin Kankam, James Baber, Edward T. Zito, Robin Hubler, Joseph Eiden, Joseph M. Severs, Shite Sebastian, Jasdeep S. Nanra, Kathrin U. Jansen, William C. Gruber, Annaliesa S. Anderson, Douglas Girgenti	51
4	Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults 2016 ·Vaccine ·Robert J. Hopkins, (unknown), (unknown), Mona Sharma, (unknown), Derek Muse, Eric Sheldon, Frank C. Hampel, (unknown)	39
5	Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study 2016 ·Advances in Therapy ·Eric Sheldon, Martin Schwickart, Jing Li, Keunpyo Kim, (unknown), Shaista Parveen, Chris Kell, Claire Birrell	36
6	A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults 2016 ·Vaccine ·Eric Sheldon, Nicholas Kitchin, Yahong Peng, Joseph Eiden, William C. Gruber, Erik W. Johnson, Kathrin U. Jansen, Michael W. Pride, Louise Pedneault	56
7	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial 2016 ·Vaccine ·C. Buddy Creech, Robert W. Frenck, Eric Sheldon, David Seiden, Martin Kankam, Edward T. Zito, Douglas Girgenti, Joseph M. Severs, Frederick W. Immermann, Lisa K. McNeil, David Cooper, Kathrin U. Jansen, William C. Gruber, Joseph Eiden, Annaliesa S. Anderson, James Baber	43
8	Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults 2014 ·Vaccine ·Robert J. Hopkins, (unknown), (unknown), (unknown), (unknown), Derek Muse, Eric Sheldon, Matthew W. Davis, Cynthia Strout, (unknown)	16
9	Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response 2012 ·Vaccine ·David N. Taylor, John J. Treanor, Eric Sheldon, Casey Johnson, Scott Umlauf, Langzhou Song, Uma Kavita, Ge Liu, Lynda Tussey, (unknown), (unknown), Alan Shaw	102
10	Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant 2012 ·The Journal of Infectious Diseases ·Murdo Ferguson, George Risi, Matthew Davis, Eric Sheldon, Mira Baron, Ping Li, Miguel G. Madariaga, Louis Fries, Olivier Godeaux, David W. Vaughn	47
11	Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study 2011 ·The Journal of Infectious Diseases ·Joanne M. Langley, George Risi, Michael S. Caldwell, (unknown), (unknown), Charles Fogarty, (unknown), Dennis Riff, Mira Baron, Louise Frenette, Eric Sheldon, (unknown), (unknown), Marc Dionne, Daniel Brüne, Linda Ferguson, David W. Vaughn, Ping Li, Louis Fries	65
12	A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults 2011 ·Vaccine ·Stan L. Block, Tingting Yi, Eric Sheldon, Filip Dubovsky, Judith Falloon	50
13	Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults 2010 ·The Journal of Infectious Diseases ·Joanne M. Langley, Louise Frenette, Linda Ferguson, Dennis Riff, Eric Sheldon, George Risi, Casey Johnson, Ping Li, Richard T. Kenney, Bruce L. Innis, Louis Fries	76
14	Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint®) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial 2008 ·Nutrition Journal ·Douglas Kalman, (unknown), (unknown), Howard Schwartz, Eric Sheldon	49
15	Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: Post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults 2008 ·Clinical Therapeutics ·Alan Kivitz, (unknown), Eric Sheldon, Qinfang Xiang, Beverly A. Jones, Arnold R. Gammaitoni, Errol Gould	39
16	Evaluation of the Comparative Efficacy of Etoricoxib and Ibuprofen for Treatment of Patients With Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial 2005 ·Mayo Clinic Proceedings ·Craig W. Wiesenhutter, Judith A. Boice, Amy T. Ko, Eric Sheldon, Frederick T. Murphy, (unknown), (unknown), Alise Reicin	55
17	Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo 2005 ·Clinical Therapeutics ·Eric Sheldon, André Beaulieu, (unknown), (unknown), (unknown), Victor S. Sloan	54
18	Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies 2005 ·Current Medical Research and Opinion ·C. Birbara, Gary Ruoff, Eric Sheldon, Claudia Valenzuela, Anthony Rodgers, Richard A. Petruschke, David J. Chang, Andrew M. Tershakovec	20
19	Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients 2004 ·Osteoarthritis and Cartilage ·Francis X. Burch, C. Codding, Nachiket Patel, Eric Sheldon	66
20	Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis 2004 ·Current Medical Research and Opinion ·Bradley S. Galer, Eric Sheldon, Nileshkumar Patel, (unknown), Francis X. Burch, Arnold R. Gammaitoni	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact